Biocytogen

Press Release

>Upcoming Events

American Association for Cancer Research (AACR) Annual Meeting 2019

The publisher: Release time:2019-03-31 viewed:849


AACR banner.png


Biocytogen Highlights


·  10 Posters highlight new IO targets (e.g. CTLA-4, OX40, CD3e), preclinical services, PK/PD studies, and antibody screening platform will be presented at AACR. Check our schedule here.


Time

Abstract Full Name

Abstract #

Board #

Category

Apr 1 

8AM - 12PM

Anti-SIRPα antibodies as a   potential weapon for cancer immunotherapy via accelerated screening in   humanized mouse models


1212


9

Experimental and Molecular   Therapeutics

Apr 1

8AM - 12PM

Novel   hCD3e mouse models for preclinical pharmacology study of therapeutic   bispecific antibody 


1469


21

Immunology

Apr 1 

8AM - 12PM

The human immune reconstituted   B-NDG mouse models are perfect tools for CART efficacy evaluation and   therapeutic antibody preclinical pharmacology study


1052


3

Tumor Biology

Apr 1

1PM - 5PM

In   vivo drug screening platform accelerated 4-1BB agonistic antibody development


2379


3

Immunology

Apr 1

1PM - 5PM

Rapid screening of anti-OX40   antibodies for cancer immunotherapy


1924


8

Tumor Biology

Apr 2

8AM - 12PM

Novel   anti-CD40 antibodies demonstrate anti-tumor activity in humanized mouse   models


3241


21

Immunology

Apr 2

8AM - 12PM

Novel CTLA-4 antibodies of   potent antitumor activity were verified in humanized mouse models


3233


13

Immunology

Apr 2

8AM - 12PM

In   vivo efficacy and safety evaluation of anti-human PD-1 and CD40 mAbs using   double humanized PD-1/CD40 mouse model


3219


29

Immunology

Apr 2

1PM - 5PM

PK-PD Modelling of An   Anti-CTLA-4 Antibody on Immune Checkpoint Humanized Mice


3906


26

Experimental
and Molecular
Therapeutics

Apr 3

8AM - 12PM

Using   humanized B-hSIRPa/hCD47 mouse model to evaluate the efficacy and toxicity of   CD47 and SIRPa antibodies


4975


28

Immunology


·  Learn about Biocytogen’s enhanced capabilities: One-stop solution from concept to IND. Extensive experience in:

o   Humanized immune checkpoint mouse models for Preclinical efficacy and pharmacology studies

o   Immune-deficient mice (B-NDG) for PDX, CDX and immune system reconstitution studies

o   Our integrated antibody discovery platform accelerates drug discovery and development

o   Customized genetically modified animal and cell models using our innovative CRISPR-based Extreme Genome Editing (EGE) technology, which increases homologous recombination (HR) efficiency by 20 times.

·  Our senior scientists and the leadership team will be available at the Meeting to discuss research strategies, collaboration, and business development opportunities. 


Come to Booth 1613 to win Starbucks and Amazon gift cards! You can schedule a face-to-face meeting HERE


Follow our LinkedIn news to keep you updated or email us at info@biocytogen.com

 


【Return list】
© 2018 Beijing Biocytogen Co., Ltd. All rights reserved. Technical support: fast help cloud